manufactured · input
The single-use prefilled pen or autoinjector that delivers a GLP-1 dose subcutaneously. The actual bottleneck in the 2022-2024 GLP-1 shortage was device + fill-finish capacity, not the active ingredient.
3
Source countries
5
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on glp-1 disposable injection pen / auto-injector somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| DKDenmark, except Greenland | 50% |
| CHSwitzerland | 28% |
| USUnited States of America | 20% |
Who makes it
5 companies produce glp-1 disposable injection pen / auto-injector.
World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.
Second-largest insulin manufacturer; invented the first commercial insulin (1923). Uses Saccharomyces cerevisiae (yeast) fermentation exclusively. Markets Humalog (lispro), Basaglar (glargine), and Lyumjev. Also dominant in GLP-1 market (Mounjaro/Zepbound). FY2024 revenue ~$45B.
Swiss self-injection device maker; YpsoMate autoinjector platform. Carved out its diabetes unit to focus on GLP-1 self-injectors and signed a long-term autoinjector supply deal with Novo Nordisk.
Major merchant manufacturer of disposable autoinjectors (Molly platform) for GLP-1 and other self-administered biologics.
UK medical-device maker; Unifine pen needles and injection devices.
